Z583 (GLXC-26150) is a chemical compound which acts as a potent and highly selective inhibitor of JAK3, and was developed for the treatment of rheumatoid arthritis.[1][2][3][4][5]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C21H22N8O2 |
Molar mass | 418.461 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Baillache DJ, Unciti-Broceta A. Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. RSC Med Chem. 2020 Sep 8;11(10):1112-1135. doi:10.1039/d0md00227e PMID 33479617
- ^ Chen C, Yin Y, Shi G, Zhou Y, Shao S, Wei Y, Wu L, Zhang D, Sun L, Zhang T. A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine-related JAK-STAT signal. Sci Adv. 2022 Aug 19;8(33):eabo4363. doi:10.1126/sciadv.abo4363 PMID 35984890
- ^ Phillips, R. Novel JAK3-specific inhibitor safe and effective in mouse RA model. Nat Rev Rheumatol 2022; 18: 551. doi:10.1038/s41584-022-00839-8
- ^ Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, Bao Z, Lu J, Li L. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023 May 19;8(1):204. doi:10.1038/s41392-023-01468-7 PMID 37208335
- ^ Jensen LT, et al. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors. eBioMedicine 2023; 97: 104840. doi:10.1016/j.ebiom.2023.104840